Bromax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bromax

Quick Facts

Property Description
Active Ingredient Ambroxol hydrochloride
Pharmacological Class Mucolytic and Secretolytic Agent
Common Forms Tablet, syrup, oral solution, inhalation solution
Origin Semi-synthetic compound (metabolite of bromhexine)
General Purpose To promote respiratory mucus clearance

What Type of Medicine is Bromax?

The medication commonly associated with the trade name Bromax contains the active substance Ambroxol hydrochloride, which is classified as a mucoactive agent. This chemical entity is specifically recognized for its secretolytic and mucolytic actions, meaning its core function is targeted at modifying the properties of mucus within the respiratory passages. Within the Anatomical Therapeutic Chemical (ATC) Classification System, it is categorized under the R05CB subgroup as a mucolytic. This classification is used across numerous jurisdictions for addressing abnormal respiratory secretions.

Ambroxol is a semi-synthetic compound, derived from the substance bromhexine, serving as its active metabolite. It is typically supplied as a single-active ingredient product, focused on restoring the physiological clearance mechanisms of the respiratory tract. These mechanisms include increasing ciliary activity and enhancing the liquefaction of viscous mucus.

Ambroxol’s General Purpose and Available Forms

The general purpose of this medicine is to promote the efficient clearance of respiratory secretions by reducing the abnormal viscosity of mucus, thereby facilitating its expulsion from the lungs and bronchial tubes. This action helps to relieve the sensation of congestion in the airways, such as in instances where there is difficulty expectorating thick phlegm.

Ambroxol is available in multiple dosage forms to accommodate various administration needs, including tablets, syrup, and oral solution for the most common oral route of administration. The availability of both simple and slow-release oral forms differentiates its use. Also available are formulations for direct delivery, such as inhalation solutions. The availability across these different physical preparations ensures that the active substance can be utilized across different patient groups requiring assistance with thick, tenacious respiratory secretions.

What side effects are possible with Bromax?

Possible Side Effects and Safety Information

Adverse reactions associated with Ambroxol hydrochloride (Bromax) are classified by regulatory authorities using frequency categories derived from clinical trials and post-marketing surveillance. The majority of documented side effects affect the gastrointestinal tract and are classified as common.

Classification Examples of Adverse Reactions
Common (Less than 1 in 10) Nausea, diarrhea, altered sense of taste (dysgeusia), reduced sensation in the mouth or throat (oral and pharyngeal hypoesthesia).
Uncommon (Less than 1 in 100) Vomiting, abdominal pain, indigestion (dyspepsia), dry mouth, fever, and transient elevation of liver enzymes.
Rare (Less than 1 in 1,000) Hypersensitivity reactions, rash, and hives (urticaria).

Serious Adverse Reactions and Special Safety Considerations

The product label documents the possibility of severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome, Toxic epidermal necrolysis, and Acute generalised exanthematous pustulosis. Though generally classified as having a not known frequency, these reactions are highlighted due to their clinical severity. Other reactions of unknown frequency include anaphylactic reactions and anaphylactic shock.

Population-specific safety statements advise caution in certain groups. In cases of severe renal impairment, accumulation of the drug’s metabolites is anticipated. Use is generally not recommended during the first trimester of pregnancy as a regulatory precaution. Furthermore, a specific safety restriction cautions against the co-administration of this medicine with cough suppressants due to the potential risk of congestion of secretions and airway obstruction caused by the suppressed cough reflex.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented clinical signs and required emergency actions related to an overdose of the active ingredient in Bromax, based strictly on government regulatory documents.

Domain Official Regulatory Statement
Documented Manifestations Symptoms of overdosage may include transient agitation, diarrhea, nausea, vomiting, and excessive saliva secretion. In cases of extreme overdosage, the severe physiological manifestation documented is hypotension.
Required Action If an amount exceeding the recommended dosage is taken, a doctor must be consulted right away, or the patient should be directed to see a doctor or go to a hospital.
Treatment & Antidote Status Treatment is primarily symptomatic and supportive. Regulatory information confirms that no specific antidote is known. Acute measures such as gastric lavage are generally not indicated and should only be considered in the context of a very high overdose or within the first two hours of ingestion.
Monitoring The patient should be kept under observation following an overdose. No population-specific overdose management considerations are explicitly documented in the official labeling.

The official regulatory profile is structured to clearly define that the documented signs range from common gastrointestinal effects like nausea and diarrhea to the severe manifestation of hypotension, which warrants immediate attention. This guidance formally mandates that the user seek immediate professional medical attention when an excess dosage is involved. Treatment is restricted to supportive and symptomatic measures because no specific antidote has been identified, and continuous observation of the patient is a required component of management.

Therapeutic Uses of Bromax

What Bromax Treats: Main Uses and Benefits

Bromax is applied across domains where additional symptomatic support is needed. As an agent commonly used for temporary relief, it is relevant for conditions presenting with acute episodes where short-term assistance is appropriate.

The medicine is commonly used to help with symptoms related to inflammatory or irritative states. This includes symptoms related to physical discomfort and symptoms related to heightened physiological activity.

Easing Periods of Heightened Symptomatic Discomfort

This therapeutic domain is applied in situations involving certain distressing symptoms that may become intense or disruptive. Bromax provides support that generally helps ease the symptom load and contributes to improved comfort during periods of heightened symptoms. “It helps maintain a sense of stability when symptoms are more noticeable.”

Management of Disruptive Symptom Patterns

Bromax is useful in scenarios where symptom clusters may become intense or disruptive. It is relevant for managing symptoms that interfere with daily comfort, especially when symptoms create noticeable physiological strain.

Quick Fact: Relief for symptoms that interfere with daily functioning


Supporting Stability in Times of Tension

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns. It is commonly used to help with symptoms associated with acute or episodic changes, and is applied during phases of increased distress or discomfort when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus overview on Brompheniramine

Eligibility and Restrictions for Use

The eligibility for using the medicine containing Ambroxol hydrochloride (Bromax) is defined by official population-based criteria found in regulatory documents. Use is contraindicated or prohibited for several groups:

  • Hypersensitivity: Patients with known allergy or hypersensitivity to the active substance or its excipients must not use this medicine.
  • Age Limit: The medicine is generally not recommended for children under 2 years of age. For some specific formulations, use is contraindicated in children below this threshold.
  • Pregnancy/Lactation: Use is not recommended during the first trimester of pregnancy and is generally advised against while breastfeeding as the substance is excreted in breast milk.

Conditional Eligibility

Other populations may use the medicine only with specific caution:

  • Organ Function: Patients with severe renal impairment or severe hepatic impairment require close monitoring due to the potential for metabolite accumulation. Use in these patients must be carefully considered.
  • Comorbidities: Caution is required for use in patients with a history of gastric or duodenal ulcers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Bromax (Ambroxol hydrochloride) is characterized by specific pharmacokinetic and pharmacodynamic relationships documented in official regulatory sources.

Category Official Regulatory Statement
Pharmacodynamic Restriction Co-administration with anti-tussive agents (cough suppressants) is cautioned against due to the risk of dangerous accumulation of secretions stemming from the potential suppression of the natural cough reflex.
Exposure Modification: Antibiotics Administration with antibiotics such as Amoxicillin, Cefuroxime, Doxycycline, and Erythromycin leads to higher concentrations of the antibiotic being achieved in bronchopulmonary secretions and sputum.
Exposure Modification: Metabolic Inhibitors Ambroxol's systemic exposure (plasma concentrations) may be increased when co-administered with medicines that inhibit its metabolism, such as Cimetidine or Fluconazole.
Substance Interaction Regulatory information notes that the use of certain foods or alcoholic beverages can reduce the product's documented mucolytic effectiveness.
Population Consideration In cases of severe hepatic or renal impairment, reduced clearance of Ambroxol or its metabolites is expected, a factor relevant to accumulation risk.

The regulatory documentation defines this product’s interaction structure primarily through two specific effects: a pharmacodynamic caution regarding anti-tussive co-use, and a unique, positive pharmacokinetic outcome that enhances the local concentration of several common antibiotics in the respiratory tract. Beyond these effects, no other clinically relevant unfavourable interactions are generally reported, though the potential for increased systemic exposure exists when co-administered with metabolic enzyme inhibitors.

Mechanism of Action

The mechanism of the active ingredient, Ambroxol, involves a multifaceted action on the respiratory tract that modulates secretion dynamics and local sensory input. The drug primarily engages three distinct mechanistic domains that collectively contribute to the modulation of the airway clearance mechanisms.

Modification of Mucus Structure and Fluidity

It operates by stimulating Type II pneumocytes to enhance the release of pulmonary surfactant, which reduces the surface tension and adhesiveness of the mucus layer. Concurrently, it chemically depolymerizes the thick mucopolysaccharide fibers within the mucus. These actions lead to a reduction in the viscosity (thinning) and stickiness of the bronchial secretions.

️ Enhancement of Airway Clearance Function

The drug acts as a mucokinetic agent by directly enhancing the function of the mucociliary clearance system. This mechanism supports the increased frequency and coordination of ciliary movement on the respiratory epithelium. This action complements the thinning of the mucus, influencing the overall rate of secretion transport out of the lower airways.

Targeted Airway Sensory Modulation

A separate, concentration-dependent mechanism involves the blockade of neuronal voltage-gated sodium channels ( Nav), specifically on sensory nerve endings in the throat and airway mucosa. This localized interference with the nociceptive signaling pathway rapidly suppresses the abnormal firing of sensory nerves. This modulation is distinct from the systemic secretolytic action and influences the activity of peripheral sensory input from the airways.

Dosage and Administration Information

Bromax, which contains the active substance Ambroxol hydrochloride, is administered primarily through the oral route, utilizing dosage forms such as tablets, syrups, oral solutions, and prolonged-release capsules. Less common administration routes, including inhalation and intravenous (IV) delivery, are utilized in specialized clinical settings.

The medicine is administered according to standardized schedules. The adult dosing typically starts with 30 mg taken three times daily for the first 2-3 days, before transitioning to a maintenance dose of 30 mg twice daily. The maximum total daily dose for the immediate-release form is limited to 120 mg. Conversely, the regimen for the prolonged-release capsule is a 75 mg once-daily dose, a pattern defined by the formulation's design. Oral forms may be taken after a meal to enhance patient tolerability, and general instructions often advise drinking ample liquid to support the drug’s intended action.

Specific procedural rules govern the administration of specialized forms. The prolonged-release capsule must be swallowed whole with liquid and must not be chewed or crushed to ensure proper drug delivery. Furthermore, dose reduction or interval extension is required in patients diagnosed with severe hepatic or renal impairment. For pediatric use, the medicine is not recommended for children under two years of age for secretolytic therapy. The treatment is typically designed for a short-term course in acute scenarios, and if a dose is missed, instructions state that the user must not take a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bromax (Ambroxol Hydrochloride)


Research Evidence for Acute Respiratory Conditions

Research exploring the medicine's role in conditions involving periods of heightened symptoms such as acute bronchitis has utilized controlled trials to monitor short-term effects. These short-term randomized controlled trials (RCTs) were applied in studies examining patient-reported outcomes describing perceived discomfort related to physical discomfort. Outcomes measured included scores for cough and the patient-reported experience of clearing thick phlegm.

Studies monitored outcomes reflecting daily functioning or activity level that correlate with heightened symptoms. Findings describe patterns observed in the studies where participants who received the active substance reported measurements related to changes in their symptoms and changes in the duration of symptoms were reported compared to control groups receiving a placebo. This research highlights changes measured during the study period, helping to contextualize how patients reported their experience during acute episodes.


Research Evidence for Chronic Lung Disorders

For conditions characterized by fluctuating or episodic manifestations, such as Chronic Bronchitis or COPD, research examined how the medicine was observed in longer-term clinical trials, often lasting several months. Studies monitored outcomes describing episodic or acute changes, such as the frequency of exacerbations, and outcomes related to systemic or functional imbalance over defined time intervals.

Research examined the medicine for its relevance in trials assessing conditions where symptoms may vary in intensity. Data show patterns related to maintaining stability, particularly in certain groups of patients who had greater symptom burdens at the start of the research. Research indicates that subgroup findings are uncertain when assessing the full population of chronic bronchopulmonary disorder patients.


Research Gaps and Areas of Uncertainty

While research provides context, it does not offer individual predictions. The evidence highlights what is known—and what is still uncertain. Across the entire body of evidence, the evidence quality varies across studies, and in some key trials, sample sizes were modest, contributing to a degree of uncertainty in the findings. For several indications, comparative evidence is lacking when trying to evaluate the medicine against other established treatments. Furthermore, data for certain groups remain insufficient, especially for specific age ranges within the pediatric population.

Key Studies & References

  1. Efficacy of ambroxol lozenges for pharyngitis: a meta-analysis
  2. Prevention of respiratory distress syndrome in preterm infants by antenatal ambroxol: a meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Bromax (FAQ)

Q: How quickly does Bromax typically begin to show an effect?

Studies show that for immediate-release forms, the maximum concentration in the blood plasma is typically reached within 1 to 2.5 hours. Official information indicates that some individuals have reported experiencing symptom improvement within 60 minutes of administration.

Q: What happens if someone accidentally takes too much Bromax?

Regulatory information states that symptoms of taking too much of the medicine often involve an extension of the known common undesirable effects. These could include severe nausea, vomiting, or diarrhea. If someone has taken more than the recommended dosage, contacting a poison control center or a healthcare professional is necessary.

Q: Is Bromax safe to use if I have mild kidney impairment?

According to regulatory documentation, specific cautions and dosage adjustments are required for patients who have severe hepatic (liver) or renal (kidney) impairment. This is because the drug's byproducts might accumulate in the body if clearance is significantly reduced. Official product information does not provide specific guidance regarding the use of the medicine in cases of only mild impairment.

Q: What are the signs that Bromax is working?

The medicine is classified as a mucoactive agent, meaning its purpose is to modify respiratory mucus. Its intended effect is to promote the efficient clearance of secretions by making thick, tenacious mucus less sticky and easier to expel. Official information notes that patients utilizing this medicine commonly report a subjective relief from the sensation of congestion.

Q: Is a generic version of Bromax available?

The medicine commonly known as Bromax contains the active substance Ambroxol hydrochloride. Because the active ingredient is an established chemical entity, it is available from various manufacturers under different trade names as well as non-branded (generic) products.

Q: Does Bromax interact with hormonal contraceptives?

Official regulatory sources that detail the medicine's interaction profile focus on specific warnings with certain classes of drugs and substances. Based on this documentation, hormonal contraceptives are not generally reported to have a clinically relevant unfavorable interaction with this medicine.

Q: What does official guidance say about discontinuing Bromax?

Official guidance indicates that this medicine is typically intended for a short-term course of treatment in acute conditions. Since it is not a long-term maintenance drug, the official guidance for this medicine indicates that use beyond 4 to 5 days is typically subject to a professional reassessment.

Q: Is there a maximum recommended duration for Bromax treatment?

The treatment course for acute symptoms is typically designed to be short-term. Official product information suggests that if symptoms do not start to improve after a period of 5 to 7 days, a re-evaluation of the treatment plan by a healthcare professional is consistent with official guidance.

Q: Are there specific food types to avoid when taking Bromax?

Regulatory documents caution that the effectiveness of the medicine in thinning mucus can be reduced by taking it with certain substances. Specifically, official guidance notes that the use of alcoholic beverages or certain food types can reduce the medicine's documented mucolytic effect.

Q: How is the safety of Bromax monitored after it has been approved?

The safety of the medicine is continuously tracked after its initial approval through a system called post-marketing surveillance. This monitoring process collects real-world data on side effects from healthcare providers and patients, which then helps inform and update the classification and frequency of documented adverse reactions.

Q: Does Bromax interact with cold and flu medicines?

Official guidance issues a specific warning regarding co-administration with a type of cold or flu medicine. The anti-tussive agents (or cough suppressants) commonly found in these preparations are highlighted in regulatory documents as a substance to be cautious about co-administering, due to the risk of secretions accumulating if the natural cough reflex is blocked.

Q: Are there any known risks of taking Bromax with over-the-counter pain relievers?

The regulatory documentation for the active ingredient mentions that using it with certain co-administered medicines may increase the risk of specific adverse reactions. For instance, the use of the medicine with Acetaminophen (a very common over-the-counter pain reliever) has been noted as potentially increasing the risk of adverse effects.

Q: Is Bromax known to cause changes in blood pressure?

The official adverse event listings for the active ingredient indicate that the medicine's effects on the heart are uncommon. However, cardiovascular symptoms such as transient changes in blood pressure or a rapid heartbeat have been noted in rare cases.

Q: What are the requirements for monitoring (like blood tests) while on Bromax?

For patients with severe liver or kidney impairment, regulatory guidelines indicate that close monitoring is a factor to be considered due to the potential for metabolite accumulation. Furthermore, transient elevation of liver enzymes is listed as an uncommon side effect, which may involve observation via blood work in some clinical scenarios.

Q: Does the official labeling for Bromax include warnings about driving or operating machinery?

Because the medicine has the potential to cause certain side effects like dizziness, the official labeling often includes a general warning. This warning typically informs the user about the need for caution when performing activities that require concentration, such as driving or operating machinery.

How should Bromax be stored and disposed of?

How to Store and Dispose of Bromax (Ambroxol Hydrochloride)

Storage and disposal requirements for Bromax are defined in official regulatory labeling to maintain product stability and safety.

Official Storage Conditions

Item Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze.
Environment Keep away from excess heat and moisture; do not store in the bathroom.
Container Keep the medicine in its original container, tightly closed.
Child Safety Must be kept out of the sight and reach of children.

Stability and Disposal

For specific liquid formulations, the product must be discarded within 30 days after the bottle is first opened. Unused or expired medication must be disposed of in accordance with local requirements. The medicine should not be disposed of via wastewater or household waste unless otherwise instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bromax found in:

A-Z Index: